Jean‐Michel Vernier

Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

Elena Ardini, Maria Menichincheri, Patrizia Banfi et al. · Molecular Cancer Therapeutics · 2016 · 312 citations · Full text

Medicine, Oncology, Pharmacology +17

RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer

Cory Iverson, Gary Larson, Chon Lai et al. · Cancer Research · 2009 · 183 citations · Full text

Medicine, Oncology, Pharmacology +17

Pharmacological Characterization and Identification of Amino Acids Involved in the Positive Modulation of Metabotropic Glutamate Receptor Subtype 2

Hervé Schaffhauser, Blake A. Rowe, Sylvia Morales et al. · Molecular Pharmacology · 2003 · 158 citations

Medicine, Neuroscience, Pharmacology +17

Group II mGlu Receptor Activation Suppresses Norepinephrine Release in the Ventral Hippocampus and Locomotor Responses to Acute Ketamine Challenge

Daniel S. Lorrain, Hervé Schaffhauser, Una C. Campbell et al. · Neuropsychopharmacology · 2003 · 94 citations · Full text

Life Sciences, Neurobiology, Neuroscience +9

(<i>S</i>)-(−)-5-Ethynyl-3-(1-methyl-2-pyrroli- dinyl)pyridine Maleate (SIB-1508Y):  A Novel Anti-Parkinsonian Agent with Selectivity for Neuronal Nicotinic Acetylcholine Receptors

Nicholas D. P. Cosford, Leo Bleicher, Audrey Herbaut et al. · Journal of Medicinal Chemistry · 1996 · 92 citations · Full text

Medicine, Neuroscience, Pharmacology +13